# Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy

> **NCT07309432** · PHASE3 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 350 (estimated)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** REGN5713
- **DRUG:** REGN5715
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07309432
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-10
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-06-15
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07309432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07309432, "Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07309432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*